
Astellas Acquires Mitobridge Under Existing Collaboration

DECEMBER 5, 2017

On November 30, 2017, Astellas Pharma Inc. and Mitobridge, Inc. announced that Astellas has exercised its exclusive option right to acquire Mitobridge under the amended terms of the [October 2013 partnership agreement](#) governing an R&D collaboration focused on discovering and developing novel drugs that target mitochondrial function. Mitobridge will become a wholly-owned subsidiary of Astellas following the close of the acquisition.

[Rosemary Reilly](#) leads the WilmerHale team representing Mitobridge in this transaction, which also includes [Steve Barrett](#), [Bill Caporizzo](#), [Jeff Hermanson](#), [Andrew Langworthy](#), [Benjamin Kelsey](#) and [Nils Remole](#).

Astellas and Mitobridge's full press release can be found on www.mitobridge.com.